Skip to main content
. 2011 Jun 2;6(6):e20598. doi: 10.1371/journal.pone.0020598

Figure 2. Activation of peritoneal NK cells in ES-2-bearing mice in response to Sin/LacZ treatment.

Figure 2

(A) 48 h after the first of 2 daily i.p. Sin/LacZ treatments, the size (forward scatter; FSC) and the granularity (side scatter; SSC) of peritoneal NK cells from Sin/LacZ treated mice (black lines) was compared to peritoneal NK cells from mock-treated mice (solid grey). Data is representative of 5 independent experiments (n = 16). (B) Using the same annotation as in A, the expression of early activation marker CD69 on peritoneal NK cells from Sin/LacZ vs. mock-treated mice is shown. 18 h and 24 h samples were taken after one treatment; 48 h samples were taken after 2 treatments; each time point represents an independent experiment (n = 3 per experiment). (C) Expression of NKG2D, FasL, and Trail on NK cells 48 h after the first of 2 daily i.p. Sin/LacZ treatments; data is representative of 2 independent experiments for NKG2D (n = 5 combined), and one experiment for FasL and Trail (n = 2). (D) The cytotoxicity of peritoneal NK cells from Sin/LacZ-treated mice was determined by incubation of peritoneal NK cells from Sin/LacZ-treated mice or splenic NK cells from mock-treated mice with YAC-1 cells, as described in materials and methods; data is representative of 2 independent experiments.